||Trustees’ Annual Report for the period|Trustees’ Annual Report for the period|Trustees’ Annual Report for the period|Trustees’ Annual Report for the period|Trustees’ Annual Report for the period|Trustees’ Annual Report for the period|Trustees’ Annual Report for the period| |---|---|---|---|---|---|---|---| |From|Period start date|||To|Period end date||| ||Day|Month|Year||Day|Month|Year| ||23|June|2022||22|June|2023| ||||||||| |Charity nam|e|||Radiotherapy UK|||| |Other name|s charity is known by|||ACCORN
Acton Radiotherapy|||| |Charityregistraton number||||1135902|||| ## **Objectives and Activities** ||SORP reference|| |---|---|---| |Summary of the purposes of the
charity as set out in its governing
document|Para 1.17|1.
To promote, support and encourage research into
radiotherapy, radiobiology and allied subjects, and the
disseminaton of the useful results of such research by
such actons as:
a.
Promotng and facilitatng multdisciplinary
collaboraton between researchers and practtoners
in radiotherapy and its allied subjects
b.
Informing patents and the public about practce and
research in radiotherapy and its allied subjects, and
engaging patents and the public in the development
of research projects
c.
Awarding grants as appropriate
2.
To advance and beneft the practce of radiotherapy and
its allied subjects to relieve sickness and preserve good
health by such actons as:
a.
Promotng and facilitatng multdisciplinary
networking and sharing of expertse and best
practce
b.
Promotng and encouraging the study of the science
and practce of radiotherapy and its allied subjects
c.
Promotng and facilitatng increased involvement of
allied professions
d.
Facilitatng development and disseminaton of best
practces in radiotherapy and its allied subjects
e.
Disseminatng knowledge concerning all aspects of
the science and practce of radiotherapy and its
allied subjects
f.
Promotng and facilitatng educaton and training in
the research and practce of radiotherapy and its
allied subjects| |Summary of the main actvites in
relaton to those purposes for the
public beneft, in partcular, the
actvites, projects or services
identfed in the accounts.|Para 1.17 and
1.19||1.
Patient information resources
The Radiotherapy UK website is a trusted source of
informaton about radiotherapy for both the radiotherapy
workforce and patents. We work with patents and in
collaboraton with like-minded organisatons to deliver
accessible informaton resources that support patents being
experts in their own care.
2.
Advocacy and Campaigning
We work in partnership with patents, academics, workforce,
industry and professional bodies to campaign for increased
access to high quality radiotherapy for all in the UK and to
raise awareness of how cost-efectve signifcant solutons
that radiotherapy ofers could positvely impact on record-
breaking wait tmes for treatment.
Radiotherapy UK is proud to be the charity partner of the
Radiotherapy4Life
campaign and
co-founder of the
#CatchUpWithCancer
campaign – a patent campaign to raise
awareness of the backlogs in cancer treatment and propose
realistc and workable solutons. We provide analysis of data
and research and media opportunites to support this work.
Our work also has global reach through our partnership with
the Global Coaliton for Radiotherapy as we work to support
other countries advocate for increased radiotherapy services
for cancer patents.
3.
Workforce engagement and support
We conduct an annual Workforce Survey to determine the
current issues faced by front-line staf, and to provide a
platorm that the mult-disciplinary workforce can share their
experiences, challenges and best practce.
Our RTUK Talks series focuses on providing opportunites for
the workforce to learn and engage with ideas, innovatons
and technologies that can support them in developing
patent-centred care and practce.
Through our Champion’s Network we support an actve
network of radiotherapy professionals who ofer frontline
insights, mutual support, educaton and research sharing. We
promote radiotherapy careers through collatng open
radiotherapy job listngs on the Daily News and to the
Radiotherapy UK website.
4.General fundraising/events
The charity raises funds from a variety of sources including
online giving, fundraising events, corporate partnerships,
donatons and grants.
The charity is developing an annual calendar of fundraising
opportunity, including an annual actve challenge and
Christmas Appeal.
The charitywas very grateful to receivegrants in this fnancial| |---|---|---|---| |||year from Astra-Zeneca, BClear and Santa Barbara Heights.
We welcomed a new ambassador for the charity, Mrs Nighat
Awan to help represent and raise awareness of the charity
and lend her expertse to support with income generaton.
5. Radiotherapy UK secretariat to APPG
We are the secretariat for the APPG for Radiotherapy,
supportng the work of the Chair and the Vice-Chairs in
organising events, meetngs, the AGM and ensuring all APPG
regulatons and requirements are met. Recent publicatons
by the APPGRT can be foundhere
.
6. Media relations
The charity campaigns have enjoyed regular press coverage
including GMTV breakfast, Sky news, ITV Tonight and all
major print publicatons. More informaton can be found
here
.
7. Communication channels
Our media channels are a very strong aspect of our work and
profle and we are well respected in our reach and content.
(i)
Daily News:This again has performed strongly with
Daily News audience having increased from 1,808 to
1,958 this year
(ii)
Twiter:The Twiter feed contnues to grow, and the
number of followers has increased to 6,212 up from
5,665 a year ago.
(iii)
Facebook:The Facebook page followers have
regularly increased and as of June 2022 stand at xx
(2022 = 2000)
(iv)
Instagram:Our following sits at 2,145 compared to
1,667 in 2021.
(v)
Website:Since the website has been re-designed it
has seen over 10,000 new visitors to the site.
8. Research and Data
The charity delivers analysis on publicly available data such as
waitng-tmes for cancer treatment and produces evidence-
based reports and research to beter understand how
radiotherapy services are currently being delivered and what
needs to change to improve patent outcomes and
experience.| |---|---|---| |4|Para 1.18|Radiotherapy UK has had regard to the guidance issued by the
Charity Commission on public beneft.
Radiotherapy UK is commited to making available to the
public, informaton regarding radiotherapy treatment and its
benefts, providing opportunites for radiotherapy
professionals to share informaton as well as campaign for
beter fundingfor radiotherapytreatment in the UK.| **Additional information (optional)** You may choose to include further statements where relevant about: ||Contributon made by volunteers|Para 1.38|Volunteers are an important part of the charity’s ability to
deliver services. We rely on volunteers to support our social
media engagement and through our Champions Network to
promote and engage with colleagues and share front-line
experiences and informaton to help inform our advocacy
work.|| |---|---|---|---|---| ## **Achievements and Performance** |**Achievements and Performance**|||| |---|---|---|---| ||SORP reference||| |Summary of the main
achievements of the charity,
identfying the diference the
charity’s work has made to the
circumstances of its benefciaries
and any wider benefts to society
as a whole.|Para 1.20||As well as the actvites noted above
,the charity has achieved
the following this year for the beneft of patents,
professionals, and the wider community:
1. Public Consultaton with benefciaries
In Summer 2022 we undertook a public consultaton with our
benefciaries – patents, carers and the wider radiotherapy
workforce. Over 500 patents/ carers res and 208 members
of the workforce responded. The aim of this consultaton
was tofocus on understanding the needs and viewpoints
of those the charity aims to work with and support.
2. Launch of Strategic Plan
In Autumn 2022 charity launched a new Strategic Plan 2023 –
2026. It sets out the directon we are heading in and how we
plan to get there. It identfes core outcomes for the charity to
focus on and is informed by the views of radiotherapy
patents and families, the radiotherapy workforce and key
charity stakeholders. htps://radiotherapy.org.uk/rtuk-
consultaton-response/
3. Patent Engagement and Informaton
From our patent and carer consultaton we discovered a huge
gap in the provision of consistent and quality informaton
about radiotherapy across the entre care pathway. Half of
respondents stated they had a 'moderate' knowledge of
radiotherapy with nearly a third knowing 'very litle or
nothing' about it.
Accurate and trusted informaton is crucial for patents so
that they understand their radiotherapy treatment, the
optons available to them, and what to expect. At present, a
patent’s experience is entrely dependent on which centre
they visit or which professional they engage with.
To address this, we have taken inital steps this year by
reviewing all existng content, creatng our frst Patent
Engagement Group and exploring how we ensure any
informaton we provide is high quality and trusted through
appropriate accreditaton.
To support delivery of our patent engagement and
informaton work we recruited a Comms & Engagement
ofcer with part responsibility for developing our patent
resources.| 4. Radiotherapy Workforce Engagement We ran our annual Workforce Flash Survey in September 2022. Over 10% of the radiotherapy workforce responded and the findings were covered by national media including BBC Newsnight and print media. This year we launched our first RTUK Talks Workforce webinar series, the first three of which had 430 registrations, with a further 2 workshops planned before the end of the calendar year. 5. Advocacy Events and Activities - Secured the support of the Daily Express to launch the first ever national newspaper campaign on radiotherapy - Helped secure crucial reforms to the radiotherapy tariff - Influenced the terms of reference of the NHS England capacity and demand review to include machine replacements, - 2 MP drop in Parliament events, each securing over 50 MPs engagement. - World Cancer Day event in Parliament with England football legend Bryan Robson OBE attended by 80 MPs. Handed in a letter calling for radiotherapy investment and a radiotherapy plan signed by the MPs to Downing Street. - Met with key Labour frontbench politicians to brief them on the need for investment in radiotherapy. - Supported Welsh parliamentarians in efforts to secure an investment of £86 million to improve radiotherapy cancer care in Wales. - Supported the All-Party Parliamentary Group for Radiotherapy with its inquiry into radiotherapy and subsequent Industry Summit to seek solutions. 6. Secretariat for the APPG Radiotherapy UK continues to act as secretariat to the AllParty Parliamentary Group for radiotherapy (APPG-RT). The group aims to be the voice in Parliament of cancer patients, their families and of those who work within the radiotherapy field. The APPG now has 55 (up from 49 the previous year) members/officers from various political parties/House of Lords. This year saw the relaunch of the APPG-RT Manifesto. 7. Research & Data We developed and launched an ‘International Comparisons Report’ to draw attention to other comparable countries that are delivering successful radiotherapy services and show what can be achieved for patients. |Additional information (optional)
You may choose to include further statements where relevant about:|Additional information (optional)
You may choose to include further statements where relevant about:|Additional information (optional)
You may choose to include further statements where relevant about:| |---|---|---| |Achievements against objectves
set|Para 1.41|N/A| |Performance of fundraising
actvites against objectves set|Para 1.41|N/A| |Other||Corporate Partnerships
The charity benefts from a number of corporate partnerships
for example Varian sponsor the charity’s Daily News bulletn.
All these partnerships are agreed on a vendor neutral basis.| ## **Financial Review** |Review of the charity’s fnancial
positon at the end of the period|Para 1.21|The Charity’s total income for this fnancial year was £128,257
Total expenditure for this year was £110,107 leaving the
charity with a year end net proft of £18,417.
During 2021/2022 The Charity has managed to contnue its
work within its limited budget by using its contacts and
generous donatons in kind (resources) from Price Jones Ltd.
The Charity is confdent that there are many untapped
avenues of funding available to the organisaton that we will
be able to avail of with the introducton of additonal
resources to focus on this area and the fnancial sustainability
of the charity.| |---|---|---| |Statement explaining the policy for
holding reserves statng why they
are held|Para 1.22|Radiotherapy UK’s policy is to provide the charity with
adequate fnancial stability and the means for it to meet its
charitable objectves. Except for such funds as the Trustees
consider prudent to maintain for the purposes of
management and administraton of the charity for the
foreseeable future, all unrestricted funds are used to the
purpose of general objects of the charity. The adequacy of the
reserves is reviewed annually.| |Amount of reserves held|Para 1.22|£196,275 (excluding the related party loan mentoned below)| |Details of fund materially in defcit|Para 1.24|The Charity has a long-term interest-free loan from related
party Price Jones Ltd which is repayable at £2,500pa. The
balance at June 2023 is £17,672| |Explanaton of any uncertaintes
about the charity contnuing as a
goingconcern|Para 1.23|There are no current uncertaintes regarding the charity
contnuing as a going concern.| |---|---|---| |**Additional information (optional)**
You may choose to include further statements where relevant about:||| |The charity’s principal sources of
funds (including any fundraising)|Para 1.47|The Charity’s main source of funds for this reportng period
were:
1.
Public Donatons via JustGiving, direct donatons and
running for radiotherapy fundraising events (to raise
awareness)
2.
Corporate donatons from: Varian Medical Systems,
AstraZeneca, Elekta, Brainlab and Flen Health
3.
Radiotherapy4Life donaton for administratve and
research analysis support.| |Investment policy and objectves
including any social investment
policyadopted|Para 1.46|We do not currently hold enough reserves to warrant an
investment policy.| |||| |A descripton of the principal risks
facing the charity|Para 1.46|Current Challenges
1.
Matching growth of charity to meet service development
needs with fnancial constraints
2.
Strained fnancial environment and COL crisis creates
difcult circumstances for fundraising
3.
Ensuring patents and benefciaries engaged with services
and organisatonal development.
4.
Developing appropriate governance structures in line
with organisatonal growth.
5.
Unstable politcal environment
6.
Contnuing crisis in delivery of cancer services
exacerbated by workforce strikes, over-bureaucracy,
limitng leadership and minimal investment.| ||Other||Future initatves
The following are considered to be priorites for the coming
year:
1.
Develop appropriate governance structures to support
charity growth and employment of staf
2.
Implement strategic plan.
3.
Co-ordinate and delivery a Radiotherapy Vision 2024.
This will be an informed, evidence-based document,
outlining what needs to happen to achieve world-class
radiotherapy in the UK by 2034. The aim of this work is
to combine the knowledge of patents, specialists,
radiotherapy leaders, frontline workforce, professional
bodies, industry and academics to create an
implementable document that will meet the needs of
cancer patents now and in the future.
4.
Develop new patent informaton resources
5.
Develop Patent Engagement and Clinical Engagement
Groups
6.
Appoint dedicated resources to generate income
7.
Develop an Income Generaton Strategy and
Communicatons Strategy.
8.
Expand our workforce engagement services
9.
Contnue to campaign and advocate for increased access
to high quality radiotherapy services across the UK|| |---|---|---|---|---| ## **Structure, Governance and Management** |Descripton of charity’s trusts:||| |---|---|---| |Type of governing document
(trust deed,royal charter)|Para 1.25|Consttuton| |How is the charity consttuted?
(e.g. unincorporated associaton,
CIO)|Para 1.25|Associaton| |Trustee selecton methods
including details of any
consttutonal provisions e.g.
electon to post or name of any
person or body enttled to appoint
one or more trustees|Para 1.25|Original Trustees were nominated and elected by the
ACORRN Scientfc Steering Commitee. New Trustees are
nominated by the same process and are elected by
consensus of the Board of Trustees of Radiotherapy UK.| ## **Reference and Administrative details** |Charityname|RadiotherapyUK(previouslyActon Radiotherapy)| |---|---| |Other name the charityuses|ACORRN| |Registered charitynumber|1135902| |Charity’s principal address|4 Abbotsbury House
139 Abbotsbury Road
London W14 8EN| Names of the charity trustees who manage the charity |1
2
3
4
5
6|Trustee name|Ofce (if any)|Dates acted if not
for whole year|Name of person (or body)
enttled to appoint trustee (if
any)| |---|---|---|---|---| ||Professor Patricia Price|Chair||Board of Trustees| ||Dr Christy Goldsmith|Secretary||Board of Trustees| ||Ms Tanya Levine|Treasurer||Board of Trustees| ||Dr Clive Harmer|Medical Advisor||Board of Trustees| ||Professor Philip Mayles|Medical Advisor||Board of Trustees| |||||| ## **Funds held as custodian trustees on behalf of others** |Descripton of the assets held in
this capacity|None| |---|---| |Name and objects of the charity on
whose behalf the assets are held
and how this falls within the
custodian charity’s objects|None| |Details of arrangements for safe
custody and segregaton of such
assets from the charity’s own
assets|None| ## **Additional information (optional)** Names and addresses of advisers (Optonal informaton) Type of adviser Name Address Name of chief executve or names of senior staf members (Optonal informaton) Sarah Quinlan – Charity Director ## **Exemptions from disclosure** ## Reason for non-disclosure of key personnel details ## **Other optional information** ## **Declarations** |The trustees declare that they have approved the trustees’ report above.
Signed on behalf of the charity’s trustees|The trustees declare that they have approved the trustees’ report above.
Signed on behalf of the charity’s trustees|The trustees declare that they have approved the trustees’ report above.
Signed on behalf of the charity’s trustees| |---|---|---| |Signature(s)||| |Full name(s)|Professor Pat Price|| |Positon (e.g. Secretary, Chair, etc|Chair|| |Date|12 August 2023|| I CHARITY COMMISSIO FOR ENGLAND AND WALE Receipts and payments accounts CC16a For the period from ?J Ub.IV2. To Section A Receipts and payments Unrestricted funds Restricte Endowme d funds nt funds Total funds Last year to the nearest toth• nearest £ tothe nearèst £ to the nearest to the nearest £ A1 Receipts Corporate donations Community Trusts and foundations 74,822 21.752 32.000 74,822 21,752 32.000 102,644 45.233 25,866 Sub total (Gross income for AR) 128,573 173,743 128,573 A2 Asset and investment sales, (see table). Sub total 128 573 128,573 173 743 A3 Payments Advocac & campaigning Charity running costs Communications Contractors Income generation IT & Development Loan repayments Patient SeNices Professional fees Promotional materials Salaries Workforce services 2,387 2,960 6,909 82,042 3,539 4,335 2,500 500 2.415 42 3,836 391 2,387 2,960 6,909 82,042 3,539 4.335 2.500 soo 2.415 42 3,836 391 1,872 2,818 16,381 43,852 13,133 2500 2500 1179 7070 Sub total 111,856 111,856 91,305 A4 Asset and investment purchases, {see table) Laptop purchases 1.056 1.056 1,056 1,056 1,036 1.036 Sub total 112912 112 912 Net of receipts/(payments) A5 Transfers between funds A6 Cash funds last year end Cash funds this year end 15,661 15,661 81.402 180,614 196,275 180,614 99.212 180,614 196,27S Section B Statement of assets a Unrestrict ed funds Restricted funds Endowment funds Categories Details to neatsst £ to nearest £ to nearest£ B1 Cash funds 196,275 Total cash funds 196,275 payments accountl511 Unrestrict ed funds Restricted funds Endowment funds to nearest £ to nearest £ to nearest £ Details Fund to which asset C05t loptionall b•longs Current value loptionall Details Fund to which asset Cost loptional) belongs Currènt value loptionall Details B4 Assets retained for the charity's own use Fund to whieh Amount du• optionall When due loptionall Details relates BS Liabilities 17,672 Signed by one or trustees on behalf of all the trustees Signature Print Name Date of approval ## **Independent Examiner's Report to the Trustees of Radiotherapy UK** I report to the trustees on my examination of the accounts of Radiotherapy UK for the year ended 22 June 2023. ## **Responsibilities and basis of report** As the charity trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011. (‘the Act’). I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act. ## **Independent examiner’s statement** I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 1. Accounting records were not kept in respect of the Trust as required by section 130 of the Act; or 2. The accounts do not accord with those records. I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report to enable a proper understanding of the accounts to be reached. Susan Redmond FCA DJH Mitten Clarke Manchester Limited Chartered Accountants St George's House 56 Peter Street Manchester M2 3NQ 16 October 2023 ## **RADIOTHERAPY UK** ## **YEAR ENDED 22 JUNE 2022 NOTES TO ACCOUNTS** ## **Interest-free loan** The charity received an interest-free loan from Price Jones Limited, a company in which one of the trustees Professor Patricia Price is a director and shareholder. The loan currently stands at £17,672 and is repayable at £2,500 per annum beginning 1 July 2017. ## **Related party transactions** During the year there was a further £2,462 (2022: £12,000) paid to Price Jones Limited. These were for general administrative costs, and costs relating to the All Party Parliamentary Group for Radiotherapy. All transactions were considered to be at arm’s length. During the year donations of £44,083 (2022:£61,680) were received from Radiotherapy4Life Limited, a company in which one of the trustees Patricia Price is a director and shareholder.